A West Australian study is investigating the impact of medicinal cannabis on the quality of life and behaviours of aged care residents living with dementia.
The study is being conducted by the Institute of Health Research, which is based at University at Notre Dame Australia’s Fremantle campus, in partnership with Israel-based pharmaceutical company MGC Pharmaceuticals.
Lead researcher Dr Amanda Timler said the study aimed to improve the quality of life of participants and relieve any negative symptoms associated with dementia.
“We are looking to monitor behavioural changes and improvements in quality of life and pain throughout the duration of the study,” Dr Timler told Australian Ageing Agenda.
The trial also aims to increase awareness about the use of medicinal cannabis in aged care facilities, said Dr Timler, who is a research officer at the Institute of Health Research.
“We are hoping to see it